The presence of various problems in the previous approval system for new drugs has caused the phenomenon of 'drug lag'.

ANBOUND’s research team is of the view that China should accelerate the import of new drugs recognized internationally while strive to enhance the R&D capabilities of the nation’s pharmaceutical companies and improve their capabilities both in developing new drugs and manufacturing generic drugs, China should also change the pharmaceutical companies’ approach of ‘take the lowest-cost’ and encourage them to produce good quality drugs at reasonable price.

Only by accelerating the reform of the existing approval system for drugs, then only China can improve the public health and sanitation services enjoyed by its residents and significantly improve the R&D capabilities of the nation’s pharmaceutical companies and promote the country’s innovations.